Company Profiles

driven by the PitchBook Platform

HemoGenyx

HemoGenyx
2013 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Reverse Merger LATEST DEAL TYPE (Announced)
$1.62M TOTAL AMOUNT RAISED
2 INVESTORS
Description

Developer of treatments for blood diseases intended to to change the way in which bone marrow or hematopoietic stem cell transplants are performed and improve their efficacy. The company's CDX bi-specific antibody & cell therapy product for BM/HSC transplantation hold the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
5 Fleet Place
London EC4M 7RD
England
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore HemoGenyx’s full profile, request a free trial.

HemoGenyx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Reverse Merger 11-Sep-2017 $1.62M Announced Pre-Clinical Trials
4. Seed Round 29-Jun-2016 000 00.000 Completed Startup
3. Product Crowdfunding 23-Sep-2015 00.000 00000 Completed Startup
2. Accelerator/Incubator $616k Completed Startup
1. Accelerator/Incubator 12-Dec-2014 $616k $616k Completed Startup
To view this company’s complete deal history including valuation and funding request access »

HemoGenyx Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
43North Accelerator/Incubator Minority 000 0000 000000 0
Start-up NY Accelerator/Incubator Minority 000 0000 000000 0

You’re viewing 2 of 2 investors.

HemoGenyx Executive Team (3)

Name Title Board
Seat
Contact
Info
Vladislav Sandler Ph.D Chief Executive Officer & Co-Founder
Alexis Sandler JD Chief Operating Officer & Co-Founder
Lawrence Pemble Chief Operating Officer

You’re viewing 3 of 3 executives.